Ginsenoside Rh2 augmented anti-PD-L1 immunotherapy by reinvigorating CD8+ T cells via increasing intratumoral CXCL10

• Main Authors: Mu-Yang Huang (Author), Yu-Chi Chen (Author), Wen-Yu Lyu (Author), Xin-Yu He (Author), Zi-Han Ye (Author), Can-Yu Huang (Author), Xin-Ling He (Author), Xiuping Chen (Author), Xiaobing Chen (Author), Baoxian Zhang (Author), Guoyin Kai (Author), Xiaolei Zhang (Author), Ting Li (Author), Mingqing Huang (Author), Jin-Jian Lu (Author)
• Format: Book
• Published: Elsevier, 2023-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Profiting from the sustained clinical improvement and prolonged patient survival, immune checkpoint blockade of programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) axis has emerged as a revolutionary cancer therapy approach. However, the anti-PD-1/PD-L1 antibodies only achieve a...